VivoSeq
Other

Chagas Disease

11

Pipeline Programs↗

4

Active Trials↗

7

Companies Involved↗

Chagas disease is an emerging landscape with 11 programs across 7 companies. The most active players are Novartis, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Sanofi. 3 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

85/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedBayer logo

Bayer

2 programs

ApprovedMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

20

clinical trials

Completed11 · 55%
Unknown status3 · 15%
Recruiting2 · 10%
Withdrawn1 · 5%
Terminated1 · 5%
Active, not recruiting1 · 5%
Other1 · 5%

Clinical Trials

Trial Activity

20 trials

Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
Recruiting·LLaboratorio Elea Phoenix S.A.·Phase 3·NCT04897516·300 enrolled
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
Recruiting·Novartis logoNovartis·Phase 2·NCT06632600·130 enrolled
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
Active, not recruiting·IInsud Pharma·Phase 3·NCT04024163·178 enrolled
Observational Pregnancy Safety Study of Women Exposed to Nifurtimox During Pregnancy to Describe the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant
Not yet recruiting·Bayer logoBayer·N/A·NCT05477953·50 enrolled
Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease
Completed·Barcelona Centre for International Health Research·Phase 4·NCT01755403·52 enrolled
Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease
Completed·DDrugs for Neglected Diseases·Phase 2·NCT03587766·45 enrolled
Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
Completed·Bayer logoBayer·N/A·NCT03784391·3,000 enrolled
Population Pharmacokinetics of Benznidazole in Children With Chagas Disease
Completed·—·N/A·NCT00699387·37 enrolled
Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 2·NCT01162967·78 enrolled
Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease
Completed·DDrugs for Neglected Diseases·Phase 4·NCT01678599·220 enrolled
New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease
Completed·Barcelona Centre for International Health Research·N/A·NCT01755377·63 enrolled
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial
Completed·IInstituto Nacional de Parasitologia Dr. Mario Fatala Chaben·Phase 3·NCT02386358·910 enrolled
A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT01377480·120 enrolled
Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.
Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 2·NCT03191162·238 enrolled
Mass Screening for Chagas Disease Among University Entrants as a Strategy to Improve Access to Diagnosis and Treatment in the Province of Salta, Argentina
Completed·Mundo Sano Foundation·N/A·NCT07033325·2,568 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)